Clinical Trial Detail

NCT ID NCT03069352
Title A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie
Indications

acute myeloid leukemia

Therapies

Cytarabine + Venetoclax

Cytarabine

Age Groups: senior adult

No variant requirements are available.